Advertisement

Clinical and Translational Oncology

, Volume 21, Issue 12, pp 1786–1787 | Cite as

Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)

  • F. J. de Haro-del MoralEmail author
  • I. Casans-Tormo
  • V. Pubul-Nuñez
  • S. Aguadé-Bruix
Correspondence

In attendance to the Editor

The working group of Nuclear Cardiology from the Spanish Society of Nuclear Medicine and Molecular Image (SEMNIM) wish to expose some comments and observations about the paper from J.A. Virizuela et al. [1]. In this paper, they affirm “baseline echocardiography, in patients at risk for heart failure (HF), helps to optimize CV therapy” and also they establish “echocardiography is deemed the technique of choice when undertaking a global comprehensive assessment of cardiac structure and function at baseline and during the cancer process. In patients with poor image quality, cardiac magnetic resonance is the best option to avoid radiation associated with nuclear medicine techniques”.

The echocardiography is the most used technique in cardiology. However, the 2D echocardiography does not provide the optimal conditions to diagnosing and following. The 3D echocardiography and strain are considered the most appropriate, but these techniques are not always available...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

For this type of study formal consent is no required.

References

  1. 1.
    Virizuela JA, García AM, de las Peñas R, Santaballa A, Andrés R, Beato C, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol. 2019;21:94–105.CrossRefGoogle Scholar
  2. 2.
    López-Fernández T, Thavendiranathan P. Emerging cardiac image modalities for early detection of cardiotoxicity derived for anticancer therapies. Rev Esp Cardiol. 2017;70:487–95.CrossRefGoogle Scholar
  3. 3.
    Zamorano JL, Lancellotti P, Rodríguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.CrossRefGoogle Scholar
  4. 4.
    Alvarez JA, Russell RR. Cardio-oncology: the nuclear option. Curr Cardiol Rep. 2017;19:31.CrossRefGoogle Scholar
  5. 5.
    Russell RR, Alexander J, Jain D, Poornima IG, Srivastavan AV, Storozynsky E, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23:856–84.CrossRefGoogle Scholar
  6. 6.
    Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.CrossRefGoogle Scholar
  7. 7.
    Doherty GJ, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/ATT/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 1019 Appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease. J Am Soc Echocardiogr. 2019;32(5):533–79.  https://doi.org/10.1016/j.echo.2019.01.008.CrossRefGoogle Scholar
  8. 8.
    ICRP. Managing patient dose in computed tomography. ICRP publication 87. Ann ICRP. 2000;30(4):7–45.CrossRefGoogle Scholar
  9. 9.
    Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac imaging with ionizing radiation. JACC Cardiovasc Imaging. 2010;3:528–35.CrossRefGoogle Scholar
  10. 10.
    Thompson RC, Soman P. Striking a balance in the discussion of the benefits of imaging tests and risks of radiation exposure. J Nucl Cardiol. 2019;26:136–7.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Grupo de Trabajo de Cardiología Nuclear de la Sociedad Española de Medicina Nuclear e Imagen MolecularMadridSpain
  2. 2.Servicio de Medicina Nuclear, Hospital Universitario Puerta de HierroMadridSpain
  3. 3.Servicio de Medicina NuclearHospital Clínico UniversitarioValenciaSpain
  4. 4.Servicio de Medicina NuclearHospital Clínico Universitario de Santiago de CompostelaA CoruñaSpain
  5. 5.Servicio de Medicina NuclearHospital Universitario Vall d’HebronBarcelonaSpain

Personalised recommendations